Lumida
/CERT
⌘K
Certara Inc

Certara Inc

CERT
$6.93USD↓-4.81%-0.35 today

MARKET CAP

1.1B

P/E (TTM)

17.8x

FWD P/E

15.9x

DAY RANGE

$7 – $7

52W RANGE

$4
$14

AI Summary

Stalk
Buy NowHigh

CERT is in a Stage 2 advancing phase with a medium-term bullish bias underscored by a confirmed Momentum Breakout and rising EMAs. Price is currently pulling back into the rising 9 EMA and 20 EMA without signs of exhaustion, offering favorable execution timing. The long-term trend remains bearish, anchored by a declining 200 DMA. Buy now to engage continuation participation on shallow pullbacks into EMAs.

  • ↑Software revenue rose 7% YoY to $49.7M in Q1 2026, driving top-line growth.
  • ↑AI integration and FDA’s animal-testing phase-out create regulatory tailwinds.
  • ↓Service revenue fell 4% in Q1 2026, reflecting Tier 1 client caution.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Certara, Inc. (NASDAQ: CERT) is a leader in biosimulation and software services tailored for the biopharmaceutical industry. The company provides innovative modeling technologies that enhance drug development processes through the integration of AI and model-informed drug development (MIDD). Certara aims to assist clients in minimizing costs and improving efficiencies during clinical trials, firmly positioning itself within the trends of digitization and advanced analytics in R&D processes.

Bull says

  • ↑Software revenue rose 7% YoY to $49.7M in Q1 2026, driving top-line growth.
  • ↑AI integration and FDA’s animal-testing phase-out create regulatory tailwinds.
  • ↑Cash of $149.5M and $82.6M in buybacks signal management confidence.
  • ↑Backlog conversion from Tier 2/3 clients expected to bolster H2 revenue.
  • ↑Strong liquidity enables continued R&D investment to improve margins.
  • ↑Full-year revenue guided at $395–405M, indicating potential stabilization.

Bear says

  • ↓Service revenue fell 4% in Q1 2026, reflecting Tier 1 client caution.
  • ↓Reported net loss of $8.8M vs. $4.7M net income prior year.
  • ↓Negative earnings yield and rising costs highlight profitability challenges.
  • ↓Ongoing securities fraud investigations add legal uncertainty and distract management.
  • ↓Short interest 25% and volatility factor 2.52 expose stock to sharp swings.
  • ↓Weak growth factor underscores risks converting backlog into revenue.

Investment themes with CERT

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-11-2026neutral

Transcript signals

Bull points

  • We know success in this market is not one-off. We live in a very connected ecosystem.
  • We're doubling down and tripling down in what we're very good at, and we'll look for partnerships to fill in some of those gaps.
  • we can accelerate timelines and drive costs down for them and help disrupt conventional flows.

Bear points

  • Total bookings in the first quarter were $115.3 million, which declined 2% from the prior year period.
  • services revenue, which was $57.2 million in the first quarter, down 4% versus the prior year period on a reported basis.
  • Services bookings in the first quarter were $66.6 million, which declined 14% from the prior year period.
Read full transcript analysis ›